Omalizumab Treatment of Systemic Mast Cell Activation Disease: Experiences from Four Cases

Internal Medicine

Volumn 50, Issue 6, 2011, Pages 611-615

  Molderings, Gerhard J ^a   Raithel, Martin ^b   Kratz, Felix ^c   Azemar, Marc ^c   Haenisch, Britta ^a   Harzer, Sabrina ^a   Homann, Jürgen ^d  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c TUMOR BIOLOGY CENTER   (Germany)

^d Evangelische Kliniken Bonn   (Germany)

Author keywords

Omalizumab; Systemic mastocytosis; Tryptase

Indexed keywords

ANTI-IGE; ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; MONOCLONAL ANTIBODY; OMALIZUMAB;

ADULT; ARTICLE; CASE REPORT; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; SYSTEMIC MASTOCYTOSIS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84857086336     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4640     Document Type: Article

References (25)

1. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37: 435–453, 2007.
2. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leuk Res 25: 603–625, 2001.
3. D'Amato G, Salzillo A, Piccolo A, D'Amato M, Liccardi G. A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma. Ther Clin Risk Manag 3: 613–619, 2007.
4. Casale TB, Busse WW, Kline JN, et al; Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117: 134–140, 2006.
5. Sands MF, Blume JW, Schwartz SA. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol 120: 979–981, 2007.
6. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 122: 569–573, 2008.
7. Molderings GJ, Haenisch B, Raithel M, et al. Omalizumab for the treatment of systemic mastocytosis: Experiences from four cases. [abstract] Naunyn-Schmiedeberg's Arch Pharmacol 381 (Suppl. 1): R91, 2010.
8. Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD. Omalizumab for the treatment of unprovoked anaphy-laxis in patients with systemic mastocytosis. J Allergy Clin Immunol 119: 1550–1551, 2007.
9. Siebenhaar F, Kühn W, Zuberbier T, Maurer M. Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy Clin Immunol 120: 213–215, 2007.
10. Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 63: 376–378, 2008.
11. Douglass JA, Carroll K, Voskamp A, Bourke P, Wei A, O'Hehir RE. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy 65: 926–927, 2010.
12. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 68: 61–76, 2009.
13. Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic responses and FcɛRI on basophils. J Allergy Clin Immunol 113: 297–302, 2004.
14. Beck LA, Marcotte GV, McGlashan DW, Togias A, Saini S. Omalizumab-induced reduction in mast cell FceRI expression and function. J Allergy Clin Immunol 114: 527–530, 2004.
15. Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 217: 65–78, 2007.
16. Puri N, Roche PA. Mast cells possess distinct secretory granule subsets whose exocytosis is regulated by different SNARE isoforms. Proc Natl Acad Sci USA 105: 2580–2585, 2008.
17. Jayapal M, Tay HK, Reghunathan R, et al. Genome-wide gene expression profiling of human mast cells stimulated by IgE or FceRI-aggregation reveals a complex network of genes involved in inflammatory responses. BMC Genomics 7: 210, 2006.
18. McGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of FceRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158: 1438–1445, 1997.
19. Noga O, Hanf G, Kunkel G, Kleine-Tebbe J. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int Arch Allergy Immunol 146: 66–70, 2008.
20. Foroughi S, Foster B, Kim N, et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 120: 594–601, 2007.
21. Chang TW, Shiung YY. Anti-IgE as a mast cell-stabilizing therapeutic agent. J Allergy Clin Immunol 117: 1203–1212, 2006.
22. McGlashan D Jr. Therapeutic efficacy of omalizumab. J Allergy Clin Immunol 123: 114–115, 2009.
23. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy 39: 788–797, 2009.
24. Alfter K, von Kügelgen I, Haenisch B, et al. New aspects of liver abnormalities as part of the systemic mast cell activation syndrome. Liver Int 29: 181–186, 2009.
25. Molderings GJ, Kolck UW, Scheurlen C, Brüss M, Homann J, Von Kügelgen I. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol 42: 1045–1053, 2007.